All Blogs
Feb 02, 2026
Cystinosis Treatment: Transforming a Life-Limiting Disorder into a Manageable Chronic Condition
Summary Approximately 1,600 prevalent cases were diagnosed across the 7MM in 2025, underscoring the condition's rarity and the concentration of patients at specialized metabolic and nephrology centers. Treatment is limited to long-standing cysteamine products, PROCYSBI, CYSTAGON/NICYSTAGON (cysteamine bitart...
Read More...
Jan 30, 2026
DAWNZERA’s EU Approval Strengthens the Hereditary Angioedema Treatment Landscape
Summary The European Commission granted marketing authorization for DAWNZERA (donidalorsen) on January 21, 2026. Developed by Ionis Pharmaceuticals and Otsuka Pharmaceutical, it is the first and only RNA-targeted therapy approved in the EU for the prevention of hereditary angioedema (HAE). Approval ...
Read More...
Jan 29, 2026
Seno Medical Secures EU MDR CE Mark for Next-Generation Imagio® Imaging System; Spine Innovation Announces FDA 510(k) Clearance of LOGIC™ Titanium Expandable Interbody System; Laborie Adds JADA® System to Obstetrics Portfolio for Rapid PPH Control; Olympus Introduces SecureFlex™ Single-Use Fine Needle Biopsy Device in the U.S.; Kardium Publishes PULSAR Pivotal Trial Findings in JACC; Myra Vision Begins U.S. ADAPT Glaucoma Study, Treating First Participant
Seno Medical’s Next-Generation Imagio® Imaging System Obtained European Union (EU) Medical Device Regulation (MDR) CE Mark Certification On January 26, 2026, Seno Medical received CE Mark certification for its next-generation Imagio® Imaging System, Model 9100, confirming that the device met the stringent ...
Read More...
Jan 28, 2026
Advances in Varicose Vein Treatment Devices: Technologies Shaping Modern Venous Care
Varicose veins, enlarged, tortuous veins most commonly occurring in the lower extremities, impact millions worldwide, causing discomfort, cosmetic concerns, and, in severe cases, complications such as venous insufficiency or ulcers. While traditional varicose vein treatments such as compression stockings and surgic...
Read More...
Jan 27, 2026
Sanofi Strengthens Amlitelimab’s Position in Atopic Dermatitis; Corcept Announces Statistically Significant Overall Survival Benefit in Phase 3 ROSELLA Study; CORXEL Raises $287M Series D1 for Cardiometabolic Pipeline Expansion; IntraBio’s Levacetylleucine Demonstrates Positive Results in Pivotal Ataxia-Telangiectasia Trial; Otsuka Secures FDA Acceptance and Priority Review for Centanafadine in ADHD
Sanofi’s Amlitelimab Demonstrates Promise in Atopic Dermatitis Following the positive findings from the COAST 1 trial (NCT06130566) reported in September 2025, two additional global Phase 3 studies, SHORE (NCT06224348) and COAST 2 (NCT06181435), have further strengthened the clinical evidence supporting amliteli...
Read More...
Jan 26, 2026
ASPAVELI Fuels Sobi’s Growth Strategy in Europe for C3G and IC-MPGN
Summary Sobi has received European Commission approval for ASPAVELI (pegcetacoplan) to treat C3G and primary IC-MPGN, two rare, progressive kidney diseases. The approval follows a positive CHMP opinion (December 2025) and marks the first approved treatment for primary IC-MPGN and the first for both C3G...
Read More...
Jan 23, 2026
JPM 2026 Recap: Who’s Winning, Who’s Catching Up, and Who’s at Risk?
The 44th Annual J.P. Morgan Healthcare Conference, held January 12-15, 2026, in San Francisco, revealed a pharmaceutical sector at an inflection point. With major blockbusters facing patent expirations, industry leaders such as Eli Lilly, Novo Nordisk, Bristol Myers Squibb, AbbVie, Bayer, Pfizer, Novartis, Roche, M...
Read More...
Jan 22, 2026
Sonomotion Secures FDA Clearance for Break Wave™ Lithotripsy System; Aidoc Earns FDA Clearance for Comprehensive AI Foundation Model in Healthcare; BD and Ypsomed Deepen Partnership to Serve Expanding Biologics Market; Omnia Medical Launches FDA-Approved PsiF DNA™ System to Market; Kardium Publishes PULSAR Pivotal Trial Findings in JACC; NEURO PMR Data Validates Hyperfine’s Diagnostic Precision and Patient-Centered Care
Sonomotion Announced FDA Clearance for its Break Wave™ Lithotripsy Device for Treatment of Kidney Stones On January 21, 2026, SonoMotion, a venture-backed medical device company focused on developing non-invasive solutions for kidney stone treatment, announced that it had received U.S. Food and Drug Admini...
Read More...
Jan 21, 2026
The Evolution of Vascular Access Devices in Modern Medicine
In the intricate world of modern clinical practice, the ability to safely and reliably access a patient's circulatory system is perhaps the most fundamental requirement of acute and chronic care. Vascular Access Devices (VADs), ranging from simple peripheral catheters to complex implanted ports, serve as the "highw...
Read More...
Jan 20, 2026
Nxera Pharma Confirms Positive Phase 3 Findings for Daridorexant in South Korea; AstraZeneca Strengthens Oncology Pipeline in China With GPC3 Armored CAR-T Rights From AbelZeta; AbbVie Shares Topline Findings from Phase 3 EPCORE DLBCL-1 Study of Epcoritamab; ImmunityBio Achieves Prolonged Complete Response Using Chemotherapy-Free CD19 CAR-NK Platform; Sobi Wins EU Approval for ASPAVELI to Treat C3G and Primary IC-MPGN
Nxera Pharma Reports Positive Phase 3 Trial Results for Daridorexant in South Korea Nxera Pharma announced top-line results from its pivotal Phase 3 clinical trial of daridorexant in South Korea, showing that the study successfully met both primary and secondary endpoints in adult and elderly patients with insom...
Read More...